![]() |
市场调查报告书
商品编码
1766252
亚磷酰胺市场机会、成长动力、产业趋势分析及 2025 - 2034 年预测Phosphoramidite Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025 - 2034 |
2024年,全球亚磷酰胺市场规模达12亿美元,预计到2034年将以7.2%的复合年增长率成长,达到24亿美元。这一市场成长主要源自于诊断、基因疗法和药物开发领域对寡核苷酸日益增长的需求。人们对基因研究和基因编辑的日益关注,以及亚磷酰胺在寡核苷酸合成中的应用日益广泛,极大地促进了市场扩张。此外,CRISPR-Cas9等治疗方法和其他分子生物学技术的进步也刺激了合成亚磷酰胺的需求。全球对分子生物学研究、基因组定序和合成生物学的关注,进一步推动了该市场的成长,尤其是在遗传疾病、传染病和癌症发病率不断上升的背景下。
需要合成寡核苷酸的标靶疗法正变得越来越普遍,从而推动了对亚磷酰胺的需求。这些疗法旨在针对特定的基因突变或致病基因,其有效性在很大程度上依赖于精准高效的寡核苷酸合成。随着基因疗法、个人化医疗和基因组研究的不断进步,对高品质亚磷酰胺的需求激增。亚磷酰胺在创建用于这些创新疗法的客製化DNA和RNA序列方面发挥着至关重要的作用,从而推动了其市场的成长。寡核苷酸在癌症治疗、遗传疾病和传染病领域的应用不断扩展,进一步推动了亚磷酰胺的需求成长。
市场范围 | |
---|---|
起始年份 | 2024 |
预测年份 | 2025-2034 |
起始值 | 12亿美元 |
预测值 | 24亿美元 |
复合年增长率 | 7.2% |
DNA亚磷酰胺市场需求依然强劲,2024年市值将达6.428亿美元。由于这些亚磷酰胺对于DNA和RNA序列的合成至关重要,其在基因治疗和分子诊断等领域的应用日益广泛。随着合成技术、纯化方法和自动化程度的提高,高品质亚磷酰胺的生产效率也随之提高,使得DNA亚磷酰胺更容易取得且更具成本效益。随着生物技术公司越来越多地将寡核苷酸的大规模生产外包,该市场将继续保持显着成长。
2024年,药物研发领域占了38.7%的市场。这主要得益于人们对需要精确寡核苷酸合成的DNA和RNA疗法日益增长的关注。各种慢性疾病对创新疗法的需求日益增长,以及PCR等早期诊断方法的进步,进一步刺激了亚磷酰胺市场的发展。对遗传和传染性疾病诊断准确性的日益增长的需求也促进了这一增长。此外,筛选方法的不断改进正在加速药物研发,并优化亚磷酰胺在研发过程中的使用。
2024年,美国亚磷酰胺市场规模达4.879亿美元,其中,分子诊断和基因治疗领域对寡核苷酸疗法的需求不断增长,推动了市场发展。包括基因治疗进展在内的基因研究投资,带动了美国资金和基础设施的增加,进一步推动了市场发展。此外,对用于DNA和RNA疗法合成以及下一代定序的高品质试剂和解决方案的需求,预计将推动美国对亚磷酰胺的需求。此外,政府的利好政策和行业领导者的加入也推动了市场的发展。
全球亚磷酰胺市场的主要参与者包括 Bioneer、PolyOrg、Biosynth、BOC Sciences、ChemGenes、Sigma-Aldrich(默克集团)、Creative Biolabs、丹纳赫、Glen Research、Hongene Biotech、LGC Biosearch Technologies、Lumiprobe、Qiagen、赛默飞世尔科技和 TriLink Bio Technologies。亚磷酰胺市场中的公司透过投资研发来巩固其地位,尤其是在基因治疗和诊断应用领域。他们专注于推进合成技术并提高生产流程效率,以降低成本并增强基于 DNA 和 RNA 的疗法的可扩展性。许多公司正在与生物技术公司建立策略合作伙伴关係,以增强其产品供应并扩大其市场覆盖范围。
The Global Phosphoramidite Market was valued at USD 1.2 billion in 2024 and is estimated to grow at a CAGR of 7.2% to reach USD 2.4 billion by 2034. This market growth is driven by the rising demand for oligonucleotides used in diagnostics, gene therapy, and drug development. The increasing focus on genetic research and gene editing, alongside the growing application of phosphoramidite for the synthesis of oligonucleotides, has contributed significantly to the market's expansion. Additionally, advancements in therapeutic methods such as CRISPR-Cas9 and other molecular biology technologies have spurred the demand for synthetic phosphoramidites. The global focus on molecular biology research, genome sequencing, and synthetic biology further fuels the growth of this market, especially with the rising prevalence of genetic disorders, infectious diseases, and cancers.
Targeted therapies that require the synthesis of oligonucleotides are becoming more common, thus driving the need for phosphoramidites. These therapies, which are designed to target specific genetic mutations or disease-causing genes, rely heavily on precise and efficient synthesis of oligonucleotides for their effectiveness. As advancements in gene therapies, personalized medicine, and genomic research continue to grow, the demand for high-quality phosphoramidites has surged. Phosphoramidites play a crucial role in enabling the creation of custom DNA and RNA sequences for use in these innovative treatments, thus fueling their growing market. The expanding applications of oligonucleotides in cancer treatment, genetic disorders, and infectious diseases further contribute to the increased need for phosphoramidites.
Market Scope | |
---|---|
Start Year | 2024 |
Forecast Year | 2025-2034 |
Start Value | $1.2 Billion |
Forecast Value | $2.4 Billion |
CAGR | 7.2% |
The demand for the DNA phosphoramidites segment remains robust valued at USD 642.8 million in 2024. As these phosphoramidites are essential for the synthesis of both DNA and RNA sequences, their use has expanded in fields such as gene therapy and molecular diagnostics. The production of high-quality phosphoramidites has become more efficient due to advancements in synthesis technologies, purification methods, and automation, making DNA phosphoramidites more accessible and cost-effective. As biotechnology companies increasingly outsource the large-scale production of oligonucleotides, this segment continues to see significant growth.
The drug discovery and development segment accounted for a 38.7% share in 2024. This is largely driven by the growing focus on DNA and RNA-based therapies that require precise oligonucleotide synthesis. The rising need for innovative therapies for various chronic diseases, along with advances in early diagnostic methods like PCR, further stimulates the market for phosphoramidite. The increasing demand for accuracy in diagnosing genetic and infectious disorders is contributing to this growth. In addition, ongoing improvements in screening methods are accelerating drug development and optimizing the use of phosphoramidite in the process.
U.S. Phosphoramidite Market was valued at USD 487.9 million in 2024, with the growing demand for oligonucleotide-based therapies for molecular diagnostics and gene therapies driving the market. Investments in genetic research, including gene therapy advancements, have led to a rise in funding and infrastructure in the U.S., further fueling the market. In addition, the need for high-quality reagents and solutions for the synthesis of DNA and RNA-based therapies, as well as next-generation sequencing, is expected to drive the demand for phosphoramidites in the U.S. The market is also benefiting from favorable government initiatives and the presence of leading industry players.
Key players in the Global Phosphoramidite Market include Bioneer, PolyOrg, Biosynth, BOC Sciences, ChemGenes, Sigma-Aldrich (Merck KGaA), Creative Biolabs, Danaher, Glen Research, Hongene Biotech, LGC Biosearch Technologies, Lumiprobe, Qiagen, Thermo Fisher Scientific, and TriLink Bio Technologies. Companies in the phosphoramidite market strengthen their position by investing in research & development, especially in the fields of gene therapy and diagnostic applications. They focus on advancing synthesis technologies and improving the efficiency of production processes to reduce costs and enhance the scalability of DNA and RNA-based therapies. Many companies are forming strategic partnerships with biotechnology firms to enhance their product offerings and extend their market reach.